Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report

doi:10.1038/s41541-023-00654-6

. 2023 Apr 12;8(1):53.

doi: 10.1038/s41541-023-00654-6.

Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report

Jane M Knisely^#^{1

2}, Lucas E Buyon^#³, Rebecca Mandt^#³, Rebecca Farkas⁴, Shobana Balasingam⁵, Karin Bok⁶, Ursula J Buchholz⁷, M Patricia D'Souza⁸, Jennifer L Gordon⁹, Deborah F L King⁵, Tung T Le⁴, Wolfgang W Leitner¹⁰, Robert A Seder⁶, Alkis Togias¹⁰, Stig Tollefsen⁴, David W Vaughn¹¹, Daniel N Wolfe¹², Kimberly L Taylor⁹, Anthony S Fauci^#¹³

Affiliations

¹ Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA. kniselyj@niaid.nih.gov.
² Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. kniselyj@niaid.nih.gov.
³ Office of Scientific Management and Operations, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
⁴ Coalition for Epidemic Preparedness Innovations, Skøyen Atrium, Askekroken 11, 0277, Oslo, Norway.
⁵ Infectious Disease, Prevention, Wellcome Trust, UK, London, NW1 2BE, UK.
⁶ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
⁷ RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, US.
⁸ Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
⁹ Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
¹⁰ Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.
¹¹ Bill & Melinda Gates Foundation, Seattle, WA, USA.
¹² Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, 200 C Street SW, Washington, DC, 20024, USA.
¹³ Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.

^# Contributed equally.

PMID: 37045860
PMCID: PMC10091310
DOI: 10.1038/s41541-023-00654-6

Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report

Jane M Knisely et al. NPJ Vaccines. 2023.

. 2023 Apr 12;8(1):53.

doi: 10.1038/s41541-023-00654-6.

Authors

Affiliations

¹ Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA. kniselyj@niaid.nih.gov.
² Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. kniselyj@niaid.nih.gov.
³ Office of Scientific Management and Operations, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
⁴ Coalition for Epidemic Preparedness Innovations, Skøyen Atrium, Askekroken 11, 0277, Oslo, Norway.
⁵ Infectious Disease, Prevention, Wellcome Trust, UK, London, NW1 2BE, UK.
⁶ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
⁷ RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, US.
⁸ Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
⁹ Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
¹⁰ Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.
¹¹ Bill & Melinda Gates Foundation, Seattle, WA, USA.
¹² Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, 200 C Street SW, Washington, DC, 20024, USA.
¹³ Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.

^# Contributed equally.

PMID: 37045860
PMCID: PMC10091310
DOI: 10.1038/s41541-023-00654-6

Abstract

On November 7th and 8th, 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), The Coalition for Epidemic Preparedness Innovation (CEPI), The Bill & Melinda Gates Foundation (BMGF), The Biomedical Advanced Research and Development Authority (BARDA), and the Wellcome Trust hosted a virtual workshop entitled “Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities.” During the workshop, researchers and vaccine developers from around the world discussed the potential of mucosal vaccines to block SARS-CoV-2 transmission and reviewed the status of SARS-CoV-2 mucosal vaccine research. Here, we summarize key challenges and opportunities in basic, translational, and clinical research that were highlighted during the meeting. We also provide recommendations to advance the field and accelerate the development of mucosal vaccines for SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Cited by

Formulation Attributes Impact Immune Profile of an Oral and Thermostable COVID-19 Subunit Vaccine.
Burlet E, Thomas N, Carwell S, Gershman BW, Morefield GL. Burlet E, et al. Vaccines (Basel). 2024 Sep 24;12(10):1087. doi: 10.3390/vaccines12101087. Vaccines (Basel). 2024. PMID: 39460254 Free PMC article.
Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19.
Valdez-Cruz NA, Rosiles-Becerril D, Martínez-Olivares CE, García-Hernández E, Cobos-Marín L, Garzón D, López-Salas FE, Zavala G, Luviano A, Olvera A, Alagón A, Ramírez OT, Trujillo-Roldán MA. Valdez-Cruz NA, et al. Microb Cell Fact. 2024 Feb 6;23(1):41. doi: 10.1186/s12934-024-02320-5. Microb Cell Fact. 2024. PMID: 38321489 Free PMC article.
Immune responses in COVID-19 patients: Insights into cytokine storms and adaptive immunity kinetics.
Zhang J. Zhang J. Heliyon. 2024 Jul 14;10(14):e34577. doi: 10.1016/j.heliyon.2024.e34577. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39149061 Free PMC article. Review.
Nanoparticle-Mediated Mucosal Vaccination: Harnessing Nucleic Acids for Immune Enhancement.
Hussain W, Chaman S, Koser HN, Aun SM, Bibi Z, Pirzadi AN, Hussain J, Zubaria Z, Nabi G, Ullah MW, Wang S, Perveen I. Hussain W, et al. Curr Microbiol. 2024 Jul 20;81(9):279. doi: 10.1007/s00284-024-03803-9. Curr Microbiol. 2024. PMID: 39031239 Review.
Immune Response of Inactivated Rabies Vaccine Inoculated via Intraperitoneal, Intramuscular, Subcutaneous and Needle-Free Injection Technology-Based Intradermal Routes in Mice.
Zhao H, Li P, Bian L, Zhang W, Jiang C, Chen Y, Kong W, Zhang Y. Zhao H, et al. Int J Mol Sci. 2023 Sep 2;24(17):13587. doi: 10.3390/ijms241713587. Int J Mol Sci. 2023. PMID: 37686393 Free PMC article.

See all "Cited by" articles

References

1. Mostaghimi D, Valdez CN, Larson HT, Kalinich CC, Iwasaki A. Prevention of host-to-host transmission by SARS-CoV-2 vaccines. Lancet Infect. Dis. 2022;22:e52–e58. doi: 10.1016/S1473-3099(21)00472-2. - DOI - PMC - PubMed
1. DeGrace MM, et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022;605:640–652. doi: 10.1038/s41586-022-04690-5. - DOI - PMC - PubMed
1. Wang R, Hozumi Y, Yin C, Wei G-W. Decoding SARS-CoV-2 transmission and evolution and ramifications for COVID-19 diagnosis, vaccine, and medicine. J. Chem. Inf. Model. 2020;60:5853–5865. doi: 10.1021/acs.jcim.0c00501. - DOI - PMC - PubMed
1. Focosi D, Maggi F, Casadevall A. Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence. Viruses. 2022;14:187. doi: 10.3390/v14020187. - DOI - PMC - PubMed
1. Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 variants of concern in the united states-challenges and opportunities. J. Am. Med. Assoc. 2021;325:1037–1038. doi: 10.1001/jama.2021.2294. - DOI - PMC - PubMed

Grants and funding

WT_/Wellcome Trust/United Kingdom

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Mostaghimi D, Valdez CN, Larson HT, Kalinich CC, Iwasaki A. Prevention of host-to-host transmission by SARS-CoV-2 vaccines. Lancet Infect. Dis. 2022;22:e52–e58. doi: 10.1016/S1473-3099(21)00472-2. - DOI - PMC - PubMed

[2] Mostaghimi D, Valdez CN, Larson HT, Kalinich CC, Iwasaki A. Prevention of host-to-host transmission by SARS-CoV-2 vaccines. Lancet Infect. Dis. 2022;22:e52–e58. doi: 10.1016/S1473-3099(21)00472-2. - DOI - PMC - PubMed

[3] DeGrace MM, et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022;605:640–652. doi: 10.1038/s41586-022-04690-5. - DOI - PMC - PubMed

[4] DeGrace MM, et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022;605:640–652. doi: 10.1038/s41586-022-04690-5. - DOI - PMC - PubMed

[5] Wang R, Hozumi Y, Yin C, Wei G-W. Decoding SARS-CoV-2 transmission and evolution and ramifications for COVID-19 diagnosis, vaccine, and medicine. J. Chem. Inf. Model. 2020;60:5853–5865. doi: 10.1021/acs.jcim.0c00501. - DOI - PMC - PubMed

[6] Wang R, Hozumi Y, Yin C, Wei G-W. Decoding SARS-CoV-2 transmission and evolution and ramifications for COVID-19 diagnosis, vaccine, and medicine. J. Chem. Inf. Model. 2020;60:5853–5865. doi: 10.1021/acs.jcim.0c00501. - DOI - PMC - PubMed

[7] Focosi D, Maggi F, Casadevall A. Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence. Viruses. 2022;14:187. doi: 10.3390/v14020187. - DOI - PMC - PubMed

[8] Focosi D, Maggi F, Casadevall A. Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence. Viruses. 2022;14:187. doi: 10.3390/v14020187. - DOI - PMC - PubMed

[9] Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 variants of concern in the united states-challenges and opportunities. J. Am. Med. Assoc. 2021;325:1037–1038. doi: 10.1001/jama.2021.2294. - DOI - PMC - PubMed

[10] Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 variants of concern in the united states-challenges and opportunities. J. Am. Med. Assoc. 2021;325:1037–1038. doi: 10.1001/jama.2021.2294. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report

Affiliations

Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous